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Abstract
 The fundamental process of protein secretion fromBackground:
eukaryotic cells has been well described for many years, yet gaps in our
understanding of how this process is regulated remain.
 With the aim of identifying novel genes involved in the secretionMethods:
of glycoproteins, we used a screening pipeline consisting of a pooled
genome-wide CRISPR screen, followed by secondary siRNA screening of
the hits to identify and validate several novel regulators of protein secretion.
We present approximately 50 novel genes not previouslyResults: 
associated with protein secretion, many of which also had an effect on the
structure of the Golgi apparatus. We further studied a small selection of hits
to investigate their subcellular localisation. One of these, GPR161, is a
novel Golgi-resident protein that we propose maintains Golgi structure via
an interaction with golgin A5.
This study has identified new factors for protein secretionConclusions: 
involved in Golgi homeostasis.
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Introduction
Protein secretion is a fundamental and well-known process in 
cell biology, in which proteins are transported from the endo-
plasmic reticulum (ER) to the Golgi via coat protein-coated 
vesicles and subsequently to the plasma membrane1–3. The 
localisation and activity of proteins involved in this secretory 
pathway must be tightly regulated to ensure correct spatio- 
temporal distribution of membranes and cargo proteins along the 
pathway. While the molecular machinery of secretion is relatively 
well understood, our knowledge remains incomplete, particularly 
regarding the regulation of protein secretion. For example, evi-
dence suggests that multiple trafficking routes for transport 
within the Golgi exist4. The complex process of sorting proteins 
at the Golgi into vesicles for their correct destinations also 
requires further investigation5–7.
Recently, genome-wide CRISPR screening has emerged as a 
powerful strategy to identify novel gene functions; this type 
of screening has the advantages of being unbiased and more 
reliable than previously-used methods, in terms of introduc-
ing genetic mutations8. As such, it provides an opportunity to 
uncover new information about the regulation of protein secre-
tion. Pooled CRISPR screening has been used for a wide range 
of applications, including the investigation of drug-resistance 
mechanisms in cancer cells9, the genetics of pluripotency10, 
autophagy regulators11,12 and host factors required for viral 
infection13. We previously demonstrated that unbiased pooled 
genome-wide CRISPR screening could effectively reveal key 
players required for glycoprotein secretion, using galectin-3 
retention at the cell surface to assess glycoprotein secretion14. 
Galectin-3 is a cytosolic protein that is secreted without entering 
the conventional secretory pathway for its export to the extra-
cellular space. Vesicular and non-vesicular modes of secretion 
have been proposed, but the precise series of events involved in 
the unconventional secretion of galectin-3 remain ill defined15. 
Once outside the cell, galectin-3 binds to β-galactosides 
resident on the cell surface16 and can therefore be used as an 
indirect measure of glycoprotein transport to the cell surface 
via the ER-Golgi secretory pathway. Using a binding partner 
of glycans as a readout, rather than one specific glycopro-
tein, allows regulators of general glycoprotein secretion to be 
discovered. It is also possible that the hits identified may 
not exclusively regulate glycoprotein secretion but may be 
more general regulators of more protein secretion; further 
experiments would be required to make this distinction.
Here, we devised a powerful experimental pipeline, using an 
improved pooled genome-wide CRISPR screen, followed by 
two arrayed secondary screening methods using siRNA knock-
down to identify new factors involved in glycoprotein secre-
tion and Golgi apparatus architecture. Combining these methods 
allows the speed and reduced cost of pooled CRISPR screening 
to be taken together with the advantages of an arrayed siRNA 
screen in which genotype and phenotype remain linked17. Using 
this approach, we were able to validate 55 novel hits that are 
important for glycoprotein secretion. We found that many of 
these hits are also important for maintenance of the Golgi archi-
tecture. One of these hits, GPR161, is a novel Golgi-localised 
protein that decreases glycoprotein secretion and disrupts the 
Golgi structure.
Methods
Cell culture
HeLa cells, suspension HeLa cells expressing Cas9 (sHeLa-
Cas9) and HeLa cells expressing horseradish peroxidase fused 
to a signal sequence to direct its secretion (HeLa-ss-HRP) were 
cultured in 10% culture medium: 10% (v/v) FBS, 100 U Peni-
cillin / 0.1 mg ml-1 streptomycin, 2 mM L-glutamine in high 
glucose DMEM, in 5% CO2 at 37°C. See Table 1 for a list of 
all reagents used and their sources.
CRIPSR screen: transduction with Brunello library
24 h before transduction, suspension HeLa cells were pas-
saged. The lentiviral Brunello library, which targets 19,114 
genes in the human genome with four unique guides per gene18, 
was used to transduce 1 × 108 suspension HeLa cells expressing 
Cas9 (sHeLa-Cas9) in polybrene media (10 µg ml-1 polybrene, 
10% (v/v) FBS, 100 U Penicillin / 0.1 mg ml-1 streptomycin, 
2 mM L-glutamine in high glucose DMEM (Sigma, D6546)) 
at an MOI of 0.50 by spinoculation at 1000 × g for 30 min at 
20°C. This gave a transduction efficiency of 40% and there-
fore an overall percentage of 31% cells with one guide per 
cell, as calculated using the Poisson distribution for the prob-
ability that a cell will be infected with at least one virus, 1− P(0, 
MOI)19. Cells were incubated for 24 h at 37°C, 5% CO2 before 
passage into puromycin media (1 µg ml-1 puromycin, 10% (v/v) 
FBS, 100 U Penicillin / 0.1 mg ml-1 streptomycin, 2 mM 
L-glutamine in high glucose DMEM). Cells were cultured in 
puromycin media for seven days to retain only transduced cells. 
The transduction efficiency was measured as the percentage 
of live cells after 48 h in puromycin media.
CRISPR screen: cell sorting by flow cytometry
Cells were washed once with DMEM, incubated with 50 µg ml-1 
anti-galectin-3 antibody conjugated to Alexa Fluor 647 for 
30 min at 4°C, then washed again. Approximately 3 × 107 
cells were sorted at the NIHR Cambridge BRC cell phenotyp-
ing hub on a BD FACS AriaIII and FACS Aria Fusion (using 
a 100 µm Nozzle and run at a pressure of 25 psi); Alexa Fluor 
647 fluorescence was detected with a 670/30 BP detector on the 
AriaIII and Aria Fusion cell sorters. Target cell population to be 
sorted was gated based on the lowest anti-galectin-3-AF647 
fluorescent signal, using Purity as sort precision mode. After 
cell sorting, cells were cultured in 20% serum media for 
24–48 h, then cultured in culture media. When the popula-
tion had expanded to 5 × 107 cells, two samples were taken; 
5 × 106 cells were frozen for guide sequencing, and 1 × 106 were 
assessed by flow cytometry. Gating leniency was decreased 
with progressive rounds, as shown in Figure 1. After the third 
sort, two distinct negative populations were observed, so a 
fourth sort was performed to separate these two populations, 
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Table 1. List of reagents.
Reagent or resource Source Identifier
Antibodies
Rat anti-galectin-3-647 mAbFlow cytometry 
concentration 50 µg ml-1
BioLegend 125408, RRID: AB_1186110
Sheep antiTGN46 pAb, IF concentration 5 µg ml-1 BioRad AHP500, RRID: AB_324049
Mouse anti-GM130 mAb, IF concentration 25 µg ml-1 BD Bioscienes 610822, RRID: AB_398141
Mouse anti-Sec31 mAb, IF concentration 25 µg ml-1 BD Bioscienes 612351, RRID: AB_39971
Mouse anti-MHC-I mAb, IF concentration 20 µg ml-1 ThermoFisher MA1-70111, RRID: AB_1076705
Rabbit anti-calnexin pAb, IF concentration 5 µg ml-1 Abcam ab22595, RRID: AB_2069006
Rabbit anti-GPR161 pAb, IF concentration 10 µg ml-1 MyBioSource MBS719938, RRID: AB_2801289
Rabbit anti-TMEM220 pAb, IF concentration 100 µg ml-1 Aviva Systems Biology ARP44467_ P050, RRID:
AB_2801328
Rabbit anti-Golgin A5 pAb, IF concentration 10 µg ml-1 GeneTex GTX104255, RRID: AB_2037117
Donkey anti-sheep IgG-568 pAb, IF concentration  
4 µg ml-1
ThermoFisher A21099, RRID: AB_2535753
Goat anti-mouse IgG-488 pAb, IF concentration  
4 µg ml-1
ThermoFisher A11001, RRID: AB_2534069
Goat anti-rabbit IgG-568 pAb, IF concentration  
4 µg ml-1
ThermoFisher A11011, RRID: AB_143157
Mouse anti-FLAG M2 mAb, IF concentration 0.5 µg ml-1 Sigma F1804, RRID: AB_262044
Cell lines
HeLa ATCC CCL-2
HeLa-HRP Gift from Vivek Malhotra As described20
sHeLa (HeLa S3) Gift from Paul Lehner Sigma, 87110901
sHeLa-Cas9 In house production As described21
Genome-wide screen library
Lentiviral Brunello David Root and John Doench, Addgene 73178-LV
Plasmids
Mouse-GPR161-FLAG Insight Biotechnology LTD MR224248
Human-TMEM220-FLAG Genescript USA INC OHu14539
Human-COL14A1-FLAG Stratech Scientific LTD HG13622-CF-SIB
Mouse-FAM98B-FLAG Insight Biotechnology LTD MR206836
Mouse-FAM102B-FLAG Insight Biotechnology LTD MR212923
Mouse-MXRA7-FLAG Insight Biotechnology LTD MR218215
Software
MaGECK https://sourceforge.net/p/mageck/wiki/Home/ Version 0.5.7
MaGECK-vispr https://bitbucket.org/liulab/mageck-vispr Version 0.5.3
GraphPad PRISM GraphPad Version 7
GO term mapper https://go.princeton.edu/cgi-bin/GOTermMapper Accessed 7th Jan 2019
CellProfiler http://cellprofiler.org/releases/ Version 3.1.5
CellProfiler Analyst http://cellprofiler.org/releases/ Version 2.2.1
Fiji https://imagej.net/Fiji/Downloads ImageJ-win64, downloaded 25th 
May 2018
R https://www.r-project.org/ Version 3.5.1 
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Reagent or resource Source Identifier
Reagents
High glucose Dulbecco’s Modified Eagle Medium 
(DMEM)
Molecular Probes D6546
Hank’s Balanced Salt Solution (HBSS) ThermoFisher 14025092
Fetal bovine serum (FBS) ThermoFisher 10270-106
L-glutamine Sigma G7513
Penicillin/streptomycin Sigma P0781
Polybrene Merck TR-1003-G
Dulbecco’s Modified Eagle Medium (DMEM) Life Technologies 21063-029
Propidium iodide Biolegend 421301
Gentra Puregene Cell kit Qiagen 158388
dNTP ThermoFisher R0191
ExTaq Takara RR001B
AMPure XP magnetic beads Beckman Coulter A63880
White 96 well CulturPlate PerkinElmer 6005680
96 well ViewPlate PerkinElmer 6005182
PBS ThermoFisher D8537
ProLong with DAPI Invitrogen P36962
Paraformaldehyde Sigma 158127
TransIT 2020 Mirus MIR 5405
Lipofectamine 2000 ThermoFisher 12566014
Phalloidin Green ThermoFisher A12379
ProLong Gold with DAPI ThermoFisher P36935
Tween 20 Sigma P1379
ECL Western Blotting Detection Reagent Amersham RPN2106
Westar XLS100 Cyanagen XLS100
Restore Plus ThermoFisher 46430
Primers and siRNA
P5 primer mix Integrated DNA Technologies See Extended data, E222
P7 primers Integrated DNA Technologies See Extended data, E322
siGenome smart pool plate Dharmacon G-CUSTOM-384690 
(see Extended data, E4)22
gating each population around a 5–10% peak. For flow cytometry 
of 1 × 106 cells after cell sorting, cells were immunos-
tained as above, with an additional propidium iodide stain 
for 5 min, and analysed on an AccuriTM C6 (BD Biosciences) 
equipped with lasers providing 488 nm and 640 nm excitation 
sources. Alexa Fluor 647 fluorescence was detected with an FL4 
detector (675/25 BP).
CRISPR screen: Library preparation and sequencing
To prepare samples for sequencing, genomic DNA from the 
different cell populations was extracted from frozen cell pel-
lets using Gentra Puregene Cell kit and concentration of DNA 
was measured on the Nanodrop. PCR was carried out in quadru-
plicate to amplify an amplicon containing the guide, with prim-
ers used to attach barcodes, stagger regions and sequencing 
adaptors for use in sequencing, as previously described by Doench 
et al.18. Briefly, each well was set up to contain 10 µg genomic 
DNA, 0.5 µM uniquely barcoded P7 primer, 0.5 µM P5 stagger 
primer mix, 200 µM each dNTP, 7.5 units ExTaq and 1x ExTaq 
buffer in a total volume of 100 µl. PCR cycles were: initial dena-
ture step at 95°C for 1 min; 28 cycles of 95°C for 30 s, 53°C 
for 30 s, 72°C for 30s; final extension at 72°C for 10 min. One 
replicate from each sample was analysed on a 2% agarose 
gel to confirm amplification was successful. PCR prod-
ucts were pooled, adding 30 µl from each PCR reaction, then 
purified using AMPure XP magnetic beads to retain only DNA 
fragments larger than 100 bp18. An equal volume of the pooled 
product and AMPure XP magnetic beads were mixed at room 
temperature for 5 min, then placed on a magnet to retain beads. 
Beads were washed three times with 70% ethanol and purified 
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Figure 1. CRISPR screen. (A) Workflow of genome-wide CRISPR screen. (B) Multiple rounds of cell sorting by flow cytometry, decreasing 
gating percentage with progressive rounds, resulted in final populations of cells with a low level of galectin-3 on the cell surface. FACS 
plots are of samples taken after cells had been expanded after cell sorting, and show cell surface galectin-3 levels as measured by 
anti-galectin-3-647 fluorescence, and viability as measured by PI. Labels of FACS plots refer to population names: N1–4 = populations after 
negative sorts 1–4; M4, cells expressing medium level of galectin-3 after sort 4. (C) Hits from populations N1 and N4; genes with a false 
discovery rate (FDR) <0.5 were defined as hit and shown in red. Genes with had guides that were enriched, but not significantly enriched 
(i.e. FDR ≥ 0.5), are shown in grey. (D) Euler diagram showing the number of hits known to be associated with organelles in the secretory 
pathway. Many ER-resident hits are lost when progressing from sorts N1 to N4. (E) Heat map of genes known to be in the secretory pathway, 
glycosylation pathway or involved in protein transport, as annotated by GO_Slim lists. Grey indicates an FDR greater than 0.5; hits are shown 
on a white-red scale, where darker red indicates a more significant FDR, closer to 0. The identity of hits changes significantly from populations 
N1 to N4.
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PCR product was eluted with 500 µl EB buffer. Sequencing 
was carried out by the CRUK genomics facility using SE50 
sequencing on the Illumina HiSeq 4000.
CRISPR screen: Bioinformatics analysis using MaGECK
Data were analysed using both MaGECK-MLE20 and 
MaGECK-RRA21 (version 0.5.7), using an enrichment (posi-
tive) sort type. In all analyses, median normalisation was used. 
PCR replicates were treated as technical replicates and sort rep-
licates were treated as biological replicates. Each population was 
given an identification code; descriptions are available in data 
file S2 (see Underlying data)22. Genes were annotated with their 
function using UniProt22, and with the organelle they reside in 
using Gene Ontology subsets23,24.
Secondary screen: HRP assay
Based on having an unknown or unclear function in secre-
tion, hits from the MaGECK analyses were selected to cre-
ate a shortlist of 368 genes to be used in a secondary screen. 
This shortlist was screened in an arrayed siRNA screen, using 
siGenome smart pools (Dharmacon) in which each plate contained 
two replicates of non-targeting siRNA as a negative control. To 
screen for conventional secretion, HeLa cells expressing ss-HRP 
were reverse transfected in with the secondary screen library, 
as previously described25. Briefly, 80 µl of 31 000 cells ml-1 
were plated into wells of a 96 well plate containing a 
mixture of 20 µl 250 nM siRNA and 0.5% (v/v) lipofectamine 
2000 in OptiMEM and incubated at 37°C, 5% CO2. Medium 
was changed to fresh culture medium 48 h after transfection. 
72 h after transfection both supernatants and cell lysates 
were assessed for HRP levels in white CulturPlate 96 well 
plates by chemiluminescence using a Tecan M1000 Pro. 
Luminescence signal from the cell lysate (CL), supernatant (SN) 
and the CL:SN ratio were each normalised to signal obtained 
from siRNA control cells according to the formula:
                     
mean background
mean siRNA control
x −
− mean background
To identify genes required for HRP secretion, a line with a gra-
dient of 1 was fit to the normalised CL vs normalised SN data. 
Outliers of this line, as identified by the ROUT method26, are 
genes that result in an up or down regulation of HRP secre-
tion. The same method was also used to identify outliers from 
the line of y = 1 for the normalised CL:SN ratio line. The 
Gene Ontology (GO) Term Mapper was used to classify hits 
identified into broad categories, using the ontology aspect 
“process” and ontology category “Generic slim” (GO_Slim) 
for Homo sapiens (GOA @EBI + Ensembl) proteins27. A gene 
was defined as related to protein transport if it was annotated 
with any of the GO_Slim annotations: transport (GO:0006810), 
transmembrane transport (GO:0055085) or vesicle-mediated 
transport (GO:0016192).
Secondary screen: Golgi morphology
HeLa cells were reverse-transfected as described above, although 
here transfected in 96-well ViewPlates. At 72 h after transfec-
tion, cells were fixed in ice cold methanol for 5 min, washed 
in PBS, stained with appropriate primary and secondary 
antibodies and ProLong with DAPI, and observed using an 
Opera Phenix High-Content Screening System to obtain unbi-
ased confocal pictures. Analysis was performed on CellProfiler28 
(version 3.1.5) to define cells and Golgi, and to measure Golgi 
intensity, size, shape and granularity. Briefly, cells were defined 
as secondary objects by propagation from nuclei, using a global 
“minimum cross entropy” thresholding method. Golgi were 
defined within a broad pixel diameter range of 2-60 px, and 
using an adaptive, two-class, Otsu thresholding method. 
The classifier of CellProfiler Analyst (CPA)29 (version 2.2.1) 
was then trained using cells randomly chosen from the whole 
experiment. These were classified as having aberrant or intact 
Golgi until the sensitivity reached an acceptable level: 82% 
and 77% for the intact Golgi and aberrant Golgi classes, 
respectively; here, 65 cells were used. The CPA classifier was 
then used to define all cells as having intact or aberrant Golgi.
Transfection with cDNA
HeLa cells at ~50% confluency were transfected with a mix of 
cDNA at 1 µg µl-1 and 0.2% (v/v) TransIT in OptiMEM. Cells 
were incubated at 37°C, 5% CO2 for 4 h, then medium was 
changed to fresh culture medium; cells were then incubated 
for a further 20 h.
Immunofluorescence microscopy
For immunofluorescence microscopy, cells were cultured on 
coverslips, fixed with either 4% paraformaldehyde in PBS for 
5 min and permeabilised with 0.1% Triton X100 in PBS for 
5 min, or fixed and permeabilised with ice cold methanol for 
5 min. Cells were then blocked in 10% (v/v) FBS / 1x PBS for 
30 min, incubated with primary antibodies for 2 h, washed three 
times with PBS, and incubated with secondary antibodies for 
30 min. Primary and secondary antibodies, and the concen-
tration they were used at for immunofluorescence, are listed 
in Table 1. Samples were mounted using ProLong Gold anti-
fade reagent with DAPI and observed using a Leica SP8 laser 
confocal microscope.
Analysis of hits
To find interacting partners of proteins of interest, we used the 
BioPlex network, a resource of proteins shown to interact by 
affinity purification-mass spectrometry30,31. Default parameters 
were used to search the network.
Co-localisation analysis
To measure co-localisation between golgin A5 and TGN46, 
17 cells were selected from each treatment from confo-
cal micrographs and analysed using the coloc 2 plugin in Fiji 
(downloaded 25th May 2018)32. For cells with TMEM220 or 
GPR161 knocked down, only cells with aberrant Golgi were 
selected from confocal micrographs to be confident that siRNA 
knockdown was effective. Pearson’s coefficient with no thresh-
old was recorded for each cell analysed. Data were tested for 
normality and equality of variance by the Shapiro-Wilk test and 
Bartlett’s K squared test, respectively. After passing normal-
ity tests, data were analysed by one-way ANOVA followed by 
Tukey HSD post-hoc test between groups. All statistical analysis 
was performed using R (version 3.5.1).
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An earlier version of this article can be found on bioRxiv, 
DOI: https://doi.org/10.1101/522334.
Results
A genome-wide CRISPR screen revealed novel regulators 
of glycoprotein secretion
We carried out a genome-wide CRISPR screen with the aim 
of identifying novel genes involved in glycoprotein secretion, 
using the level of galectin-3 on the surface of live cells to look at 
glycoprotein secretion via the ER-Golgi pathway. The work-
flow for the screen is shown in Figure 1A. Suspension HeLa 
cells stably expressing Cas9 were transduced with the Brunello 
lentiviral guide (sgRNA) library, an optimised library for the 
human genome18, at a low multiplicity of infection such that the 
majority of the transduced cells received exactly one sgRNA. 
After transduction, we performed three rounds of cell sorting by 
fluorescence activated with increasing selection stringency 
for low levels of cell surface galectin-3. This method initially 
allows more cells through cell sorting, then becomes gradu-
ally more stringent by decreasing the gating percentage, increas-
ing the number of true positives in later sorted populations. This 
resulted in the enrichment of two distinct populations with low 
levels of cell-surface galectin-3 after the third sort, in popu-
lation N3 (Figure 1B). As there are lots of cells with very 
little or no galectin-3 on the cell surface in population N3, the 
other populations may have more galectin-3, transferred from 
the extracellular pool, or a higher effective concentration of 
anti-galectin-3 antibody. A fourth round of cell sorting was used 
to separate these distinct populations, resulting in populations 
M4 and N4 (Figure 1B). We extracted genomic DNA from all 
populations and carried out deep sequencing to determine the 
raw sgRNA counts in each population, available in data file S1 
(see Underlying data)22. MaGECK analysis allowed the iden-
tification of hits from population N1 onwards; full MaGECK 
results are available in data file S2 (see Underlying data)22. 
Hits enriched in populations N1 and N4 are shown in Figure 1C.
The identity of the hits changed as cell sorting progressed. 
This was particularly true of hits which localise to the ER: in 
total, 64 hits localise to the ER in population N1, compared 
to 29 in population N4 (Figure 1D). As many genes in the ER 
are involved in critical biological processes, it is likely that 
these genes were lost in later sorts as cells lacking these genes 
have a growth or survival defect. For example, many of the 
enzymes involved in N-linked glycosylation, such as the 
asparagine-linked glycosylation (ALG) enzymes ALG1, ALG3, 
ALG5, ALG6 and ALG8, are identified as hits in population 
N1 but are lost in N4. Conversely, some hits are enriched after 
multiple cell sorting rounds in N4 but were not identified in N1 
(Figure 1E). As such, we took a selection hits from across all 
populations forward into the secondary screen. MaGECK-
MLE and MaGECK-RRA analysis revealed that there is little 
difference between the later populations: N3, M4 and N4 (data 
file S2, see Underlying data)22. As we intended to validate 
hits with further screening, we used a false discovery rate 
(FDR) of 0.5 to classify hits. This lenient FDR is validated by 
the presence of hits previously shown to play a role in secretory 
and glycosylation pathways, such as ribosomal proteins involved 
in protein translocation into the ER machinery, enzymes 
involved in N-linked glycosylation, RAB proteins and trafficking 
protein particle complex (TRAPPC) proteins (Figure 1E). This 
shows that our screen was very efficient in identifying previ-
ously described regulators of glycoprotein secretion. Additionally, 
there were many hits identified that did not have a clear link to 
functions in protein secretion. Therefore, we hypothesised that 
many genes enriched in our screen with either no character-
ised function, or with no described function in the secretory 
pathway, may be new regulators of protein secretion.
An RNAi secondary screen validated hits from the CRISPR 
screen
Due to the lenient FDR used for MaGECK, it was important to 
validate the hits. Around 400 hits, identified from populations 
N1 - N4/M4 of the CRISPR screen, were selected for validation 
by secondary screening. Of these 400 hits, 113 had no anno-
tated function in UniProt; 32 also had no GO annotations. As 
many of these hits were uncharacterised, they had the potential 
to represent novel regulators of protein secretion. Twelve 
positive controls annotated with GO terms related to protein 
secretion were also included in the screen to validate the 
statistical analysis. For secondary screening, we used siRNA 
knockdown of hits in HeLa cells that stably express ss-HRP, 
which is a glycosylated protein secreted into the extracellular 
space33,34. HeLa-ss-HRP were transfected with arrayed siRNA in 
a 96 well plate. At 72 h after transfection, we collected the super-
natant, lysed the cells and assessed HRP by chemiluminescence. 
Knockdown that led to a decrease in the ratio of superna-
tant luminescence to cell lysate luminescence indicated genes 
that were important for glycoprotein secretion. Knockdown 
of 92 of the genes screened resulted in less secretion of HRP 
(Figure 2A). Positive controls also resulted in less HRP secre-
tion, as expected (Figure 2A, B). The 92 genes validated by 
the siRNA screen are listed in Figure 2B and 2C. Of these hits, 
55 were not annotated with GO_Slim terms related to secretion 
or protein transport; 22 of these had no GO_Slim annotations 
and 6 had no GO annotations at all (Figure 2C).
Further screening revealed many genes with altered 
glycoprotein secretion also had a fragmented aberrant 
Golgi apparatus
To further probe how the identified genes affect glycopro-
tein secretion, the 92 genes identified in the HRP screen were 
further analysed for changes in Golgi apparatus morphol-
ogy using the same siRNA knockdown. At 72 h after siRNA 
transfection, cells were fixed and analysed by immunofluores-
cence, using an antibody against GM130, a marker of cis-Golgi 
membranes. Images were collected and classified as having 
aberrant or intact cis-Golgi using the machine learning plat-
form within CellProfiler, as shown in Figure 3A and 3B 
(raw results are provided in S6, Underlying data)22. Many 
of the silenced genes resulted in an increase in aberrant 
cis-Golgi compared to the control (~20%). Genes with more than 
the median percentage of cells with aberrant Golgi are shown in 
Figure 3C, and all genes are shown in Figure E1 (see Extended 
data)22. Based on having unknown functions in secretion, five 
genes from the top half of these hits were chosen to further 
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Figure 2. Horseradish peroxidase (HRP) screen to  identify genes  important  for secretion. Approximately 400 genes were screened 
in an arrayed siRNA knockdown format. (A) Mean of the normalised luminescence for both cell lysate and supernatant signals from two 
independent replicates. ~400 genes were screened; those with significant divergence from control siRNAs, as identified by the ROUT 
method, are indicated by a green cross (x). Twelve genes known to be involved in secretion or protein trafficking were included in the screen 
as positive controls, indicated by a blue plus (+); these known controls were also identified as hits, validating the statistical method used 
here. (B, C) Mean values for normalised luminescence for cell lysate and supernatant (SN) signals of the 92 hits identified. Here these hits 
are shown on a white-red scale, where darker red indicates a greater secretion defect. The generic GO_Slim was used to categorise hits as 
either related to protein transport, unrelated to protein transport or not annotated. (B) A gene was defined as related to protein transport if it 
was annotated with any of the GO_Slim annotations transport (GO:0006810), transmembrane transport (GO:0055085) or vesicle-mediated 
transport (GO:0016192). (C) Genes unrelated to protein transport or not annotated by GO_slim terms represent novel hits involved in protein 
secretion. Of the genes with no GO_Slim annotations, genes with no GO annotations at all are indicated in italics. Genes defined as not related 
to protein transport have other annotations in the generic GO_Slim.
investigate the mechanism by which these hits lead to a secre-
tion defect: GPR161, TMEM220, FAM98B, FAM102B and 
MXRA7. We confirmed that the knockdown of these five genes 
led to a perturbation in the architecture of the Golgi and affected 
protein secretion. This can be seen by the more diffuse locali-
sation of two Golgi-resident proteins, TGN46 and GM130; 
by the more diffuse localisation of SEC31, a marker of ER exit 
sites; and by the defect in the transport of the glycoprotein 
MHC-I to the cell surface (Figure 3D).
Subcellular localisation of new regulators of glycoprotein 
secretion
Given the poor characterisation of GPR161, TMEM220, 
FAM98B, FAM102B and MXRA7 in the literature and the limited 
resources available to study their localisation, we obtained 
cDNA constructs of each of these gene fused to a FLAG-tag, to 
study the localisation of the protein inside the cells (Figure 4). 
HeLa cells were transiently transfected with cDNA, then fixed 
24 h after transfection. Fixed cells were immunostained for 
FLAG and either calnexin or TGN46, markers of the ER and the 
Golgi, respectively. GPR161 localised to the Golgi, as seen by 
its co-localisation with TGN46 (Figure 4A), whereas TMEM220 
and MXRA7 both partially colocalised with calnexin, indicat-
ing that they are found at the ER (Figure 4B, C). FAM98B was 
primarily found in the cytosol, with a portion of FAM98B 
also localising to the nucleus (Figure 4D). Finally, FAM102B 
was found both at the plasma membrane and in the cytosol 
(Figure 4E). However, it is important to note that the over-
expression of these FLAG-tagged constructs may not reflect 
the endogenous protein localisation, as some dominant 
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Figure 3. Further secondary screen for altered Golgi morphology. (A) Workflow of Golgi morphology screen. (B) Training set used to 
train the CellProfiler Analyst (CPA) classifier to distinguish between fragmented and intact Golgi. Using this training set, sensitivity was 
77% for fragmented Golgi class and 82% for the intact Golgi class. Examples of control and test images classified using CPA are also shown. 
Cells with fragmented Golgi are labelled with 1; cells with intact Golgi are labelled with 2. (C) Percentage of cells with fragmented Golgi for 
the top 48 hits from tertiary screen. Hits are arranged alphabetically and coloured by cell count, with darker blue spots representing more 
confluent wells. Five of these hits were further characterised, indicated with blue rectangles. (D) Immunostaining of HeLa cells (original 
magnification 20x) treated with siRNA to knockdown each of the five genes indicated above the images. Cells were stained with the antibodies 
against the proteins indicated in green or red on the left. For all images, DAPI staining is shown in blue.
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Figure 4. Localisation study for new regulators of glycoprotein secretion. Fluorescence microscopy images of HeLa cells expressing 
a FLAG-tagged cDNA construct show each protein’s localisation by co-staining with either an ER marker, calnexin, or a Golgi marker, 
TGN46. In the merged images, FLAG staining is shown in green and calnexin or TGN46 staining is shown in red. The subcellular localisation 
of each protein construct is indicated in green on the cell diagrams. Darker shades of green are used to indicate the most prominent 
location if the construct localises to more than one compartment. A–E show expression of FLAG-tagged GPR161 (A), TMEM220 (B), MXRA7 
(C), FAM98B (D) and FAM102B (E). Original magnification 20x.
negative effect might happen when using the cDNA con-
struct. We believed this was the case for TMEM220, as the 
TGN46 immunostaining seems compromised in the transfected 
cells (Figure 4B). It was therefore important to validate the 
localisation of the protein using specific antibodies. We stud-
ied the localisation of the endogenous proteins GPR161 and 
TMEM220 and confirmed that GPR161 localised mainly in the 
Golgi (Figure 5Ai). This was further demonstrated using siRNA 
against GPR161; here the Golgi localisation of GPR161 disap-
peared (Figure 5Bi). However, endogenous TMEM220 localised 
to the Golgi (Figure 5Aii), in contrast to the cDNA overexpres-
sion showing an ER localisation. This Golgi residence was simi-
larly confirmed using siRNA (Figure 5Bii). It is therefore likely 
that the overexpression of TMEM220 causes a perturbation 
in the trafficking of proteins from the ER to the Golgi.
GPR161 is a novel Golgi resident protein involved in 
protein secretion
Our study shows that GPR161 is a new Golgi-resident protein. 
To understand its role in secretion, we used the BioPlex network, 
a resource of proteins shown to interact by affinity purification- 
mass spectrometry, to look at its interacting partners30,31. 
Interestingly, the BioPlex network shows that GPR161 inter-
acts with golgin A5 (also known as golgin 84). Golgin A5 is a 
coiled-coil membrane protein that plays a role in intra-Golgi 
vesicle capture35 and contributes to maintaining Golgi mor-
phology, likely by its interaction with Rab1A36–38. We showed 
that golgin A5 and GPR161 colocalised (Figure 5C), and the 
knockdown of GPR161 decreased the colocalisation between 
golgin A5 and TGN46 (Figure 5D). This appears to be specific 
to GPR161, since the knockdown of TMEM220, which we also 
found localises to the Golgi, resulted in similar perturbation of 
Golgi, but did not affect golgin A5-TGN46 colocalisation. There-
fore, an aberrant Golgi structure alone does not change golgin 
A5 localisation to the Golgi (Figure 5D). These data suggest that 
GPR161 may serve to recruit golgin A5 to the Golgi membrane.
Discussion
Here we identified novel genes involved in glycoprotein secre-
tion using a combination of pooled CRISPR screening and 
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Figure 5. GPR161 and TMEM220, two novel Golgi-resident proteins involved in protein secretion, regulate glycoprotein secretion by 
different mechanisms. (A) Colocalisation microscopy shows that both (i) GPR161 and (ii) TMEM220 colocalise with TGN46 and GM130, 
two Golgi markers, and not with calnexin, a marker of the ER. (B) siRNA knockdown of (i) GPR161 or (ii) TMEM220 demonstrates that the 
antibodies used to detect these endogenous proteins only specifically detect protein at the Golgi. (C) GPR161-FLAG (red) colocalises 
with golgin A5 by microscopy. (D) Microscopy shows that knockdown of both GPR161 and TMEM220 lead to Golgi fragmentation seen by 
the TGN46 staining, but only GPR161 knockdown results in less colocalisation of golgin A5 and TGN46. Quantification of this change in 
colocalisation, measured by Pearson’s coefficient, shows that GPR161 knockdown cells have significantly less colocalisation than control 
cells (***p < 0.001), but there is no significant difference in colocalisation between control cells and TMEM220 knockdown cells (p = 0.302). 
Original magnification 20x.
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siRNA screening. This work expands on our results from a 
previous CRISPR screen measuring cell-surface galectin-3, 
which had identified a number of regulators of glycosylation 
and protein trafficking; however, most of those hits had had 
well-known functions14. Although galectin-3 itself is uncon-
ventionally secreted, this type of screen should primarily iden-
tify genes responsible for the transport of glycoproteins to the 
cell surface, as secreted galectin-3 can be transferred between 
cells14,39. Here, we sought to build on the findings of our previ-
ous screen by using galectin-3 to identify novel proteins with 
roles in glycoprotein secretion. We used the improved Brunello 
sgRNA library18 rather than GeCKOv2 library, and an altered 
cell sorting strategy which would allow more hits through 
cell sorting initially, in order to increase the number of true 
positives in later populations. The Brunello library is an 
optimised library for the human genome, which was designed 
to increase the percentage of active guides while reducing off 
target effects compared to other libraries18. Furthermore, here 
we analysed populations at all stages of cell sorting rounds 
performed, rather than only the final sorted population.
Overall, our data suggest that the enhanced cell sorting strat-
egy we employed here does improve results. While there is 
little enrichment visible by anti-galectin-3 staining in the ear-
lier sorted populations, deep sequencing showed that enrich-
ment had taken place. Many of the hits enriched in the first 
sorted population, N1, localise to the ER and the plasma mem-
brane; later populations had fewer hits localised to the ER. This 
is likely due to problems with cell survival; over the extended 
time period and stress derived from the four sorts, cells with ER 
defects may be less able to survive. Enrichment of two distinct 
galectin-3 negative populations was visible by flow cytometry 
after the third round of cell sorting, in population N3. The most 
negative population within N3 consisted of cells that had little 
or no galectin-3 bound to the cell surface but were still able to 
secrete galectin-3 into the supernatant, so the excess of extracel-
lular galectin-3 could bind to both the mid-negative population 
and the unaffected population of cells. Combined with the 
higher effective concentration of anti-galectin-3 antibody during 
staining, this meant that the unaffected population appeared 
to have more galectin-3 staining after earlier sorts. Across 
all sorted populations, the enrichment of many hits that are 
known to be in secretory and glycosylation pathways provides an 
initial validation of the success of the CRISPR screen. In 
comparison to our previous screen, we identified more 
hits known to have roles in the maturation or secretion of 
glycoproteins; moreover, we found a much higher number of 
genes not known to have such roles. These hits may have roles 
is wider protein secretion; further work is required to investigate 
this possibility.
Due to the large number of hits identified by the MaGECK 
algorithms, we selected hits to be taken forward for second-
ary screening for protein secretion. Via this screening method, 
we identified 92 hits that result in a secretion defect, of which 
55 are not annotated with GO terms related to secretion. The 
92 hits validated for secretion represent approximately one 
quarter of the hits screened, highlighting the importance of 
secondary screening after a CRISPR screen due to the high 
chance of false positives. However, the fact that 55 of the 
validated hits have previously unknown or unclear functions in 
secretion demonstrates the power of this screening strategy. 
In comparison to other siRNA screens investigating protein 
secretion, there is very little overlap with our validated list of 
92 hits40–42; however, this is not surprising as many of our hits 
taken forward for secondary screening were selected based on 
having an unclear function in protein secretion. Addition-
ally, these screens looked specifically at the early secretory 
pathway40, or started with smaller-scale libraries41,42, so an over-
lap of hits after secondary screening in the different pipelines 
may not be expected. To further validate these hits, we inves-
tigated Golgi morphology. There was a clear increase in the 
percentage of cells with aberrant Golgi morphology for many 
of the hits. As siRNA knockdown efficiency was not quanti-
fied for each gene, the percentage of cells with aberrant Golgi 
does not give a definitive ranking of the scale of the effect each 
gene has on protein secretion. Additionally, while the pres-
ence of aberrant Golgi morphology gives a reason for the altered 
secretion and therefore validates both the CRISPR screen 
and HRP assay results, it does not explain how each indi-
vidual gene product contributes to protein secretion. As such, 
we selected five hits with little known about their function in 
protein secretion to investigate further. Most of these had very 
strong phenotypes in both assays, such as MXRA7, but 
some had a weaker, yet still significant, phenotype, including 
GPR161; we studied this selection in order to validate the full 
list of genes as a resource for further investigation.
Among the five hits that we studied for further mechanistic 
insight, GPR161 and TMEM220 localised to the Golgi, whereas 
MXRA7 localised to the ER. FAM98B and FAM102B local-
ised to the cytosol or the plasma membrane. Further studies 
will be required to fully understand how each gene regulates 
protein secretion. Interestingly, a recent study has shown the 
importance of the extracellular matrix (ECM) in regulating 
Golgi organisation and function via the activation of ARF143. 
MXRA7, a component of the ECM, might play a similar role. 
Little is known about FAM98B and FAM102B, but FAM102B 
shows a clear localisation at the plasma membrane, so it could 
regulate protein secretion through an identified signalling 
pathway. FAM98B shows cytosolic and nuclear localisation, 
and interacts with other such proteins to form a complex involved 
in shuttling RNA between the nucleus and cytoplasm44, suggest-
ing that FAM98B may affect protein secretion by a transcriptional 
route.
Our further investigation of the two proteins that localised to 
the Golgi, TMEM220 and GPR161, suggests that they regu-
late Golgi morphology by different mechanisms. TMEM220 
is a transmembrane protein that has been shown to interact 
with both actin and testis-specific glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) in the BioPlex network30,31. Actin, 
and the cytoskeleton in general, is well known to contribute to 
protein trafficking along the secretory pathway; for example, it is 
recruited to the Golgi to by a complex of SPCA1 and active cofi-
lin, where it is suggested to form a membrane domain required 
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to initiate sorting of secretory cargo7,33,45. It is possible that 
TMEM220 acts as an anchor for actin on the Golgi membrane. 
This possibility needs to be further investigated using in vitro 
experiments. Alternatively, TMEM220 could affect protein 
secretion via an interaction with GAPDH, which has recently 
been implicated in protein secretion via the inhibition of COPI 
vesicle biogenesis46.
GPR161 is a G-protein-coupled receptor (GPCR) that is involved 
in neural tube development and acts as a regulator of cell sig-
nalling pathways, including Shh signalling, protein kinase A 
(PKA) signalling, retinoic acid signalling and Wnt signalling47,48. 
This was a particularly interesting hit as it has recently 
become clear that GPCRs function at membranes other than 
the plasma membrane49, and previous work has suggested that 
a Golgi-resident GPCR regulates transport from the Golgi, 
although the specific GPCR involved remains unknown50. Our 
results showing that GPR161 is both localised to the Golgi 
and involved in regulation of Golgi morphology and glycopro-
tein traffic fit with this emerging idea that GPCRs can regu-
late protein trafficking. The BioPlex network for GPR161 
shows an interaction with golgin A5, as well as with five PKA 
subunits30,31; other work has also demonstrated an interac-
tion between GPR161 and PKA51. The interaction with PKA 
subunits is interesting, as a PKA signalling pathway has pre-
viously been shown to regulate retrograde transport from the 
Golgi to the ER, which indirectly also affects anterograde 
traffic52. However, previous work found that PKA regulatory 
subunits binding to GPR161 results in its transport to the plasma 
membrane to signal through PKA51. Here, we did not observe 
any localisation of either overexpressed or endogenous GPR161 
at the plasma membrane, suggesting that a different mechanism 
may be important here. Furthermore, our data suggest that 
the interaction between GPR161 and golgin A5 is important 
for maintenance of the Golgi architecture and function. One 
mechanism for this may be that GPR161 acts to recruit golgin 
A5 to the Golgi. To confirm this mechanism, further experiments 
involving mutated forms of GPR161 and golgin A5 will have 
to be performed, along with higher resolution imaging. 
In summary, here we describe an optimised CRISPR screen-
ing strategy that successfully identifies new regulators of glyco-
protein secretion. Our secondary screening validated 55 hits not 
previously known to be directly involved in protein secretion; 
many of these hits also regulate Golgi morphology. We hope that 
these validated hits can serve as a resource for other research-
ers investigating protein secretion and Golgi morphology. We 
also highlight GPR161, a particularly interesting protein given 
that Golgi-localised GPCRs have recently been implicated in 
protein trafficking. We find that it is a novel Golgi-localised 
protein that appears to interact with golgin A5 in order to 
maintain Golgi structure.
Data availability
Underlying data
Raw sequencing files from deep sequencing of the screened 
populations on Gene Expression Omnibus, Accession number 
GSE133692: https://identifiers.org/geo/GSE133692.
Apollo: Research data supporting ‘Genome-wide CRISPR 
screening identifies new regulators of glycoprotein secretion’. 
https://doi.org/10.17863/CAM.4040822 
This project contains the following underlying data:
–    S1.xlsx (sgRNA counts of unsorted and sorted population 
from the CRISPR screen)
–    S2.xlsx (MaGECK [version 0.5.7] analysis of sgRNA 
counts from the CRISPR screen. Both MaGECK-MLE and 
MaGECK-RRA results are shown. False discovery rates 
[FDR] from this table were used to create Figure 1C–E)
–    S3.zip (raw FCS files from flow cytometry staining of 
sorted samples, used to create Figure 1B).
–    S4.xlsx (raw chemiluminescence data, used to create 
Figure 2)
–    S5.zip (unedited image files used in Figure 3D, Figure 4 
and Figure 5)
–    S6.xlsx (data output from Cell Profiler, showing total 
number of cells identified per image and number of cells 
classified as having fragmented or intact Golgi)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Extended data
Apollo: Research data supporting ‘Genome-wide CRISPR 
screening identifies new regulators of glycoprotein secretion’. 
https://doi.org/10.17863/CAM.40408 
This project contains the following extended data:
-    E1.pdf (all hits from the secondary screen for Golgi 
morphology, top hits of which are shown in Figure 3C)
-    E2.xlsx (sequence of P5 primers used for PCR amplification 
of sgRNA)
-    E3.xlsx (sequence of P7 primers used for PCR amplification 
of sgRNA)
-    E4.xlsx (details of the siGenome pooled siRNA library 
used in secondary screening)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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RNAi efficacy (important for Figure 5) is not validated anywhere that I could see. 
 
The colocalization analysis is limited. GolginA5 and TGN46 should not overlap significantly as they
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 The colocalization analysis is limited. GolginA5 and TGN46 should not overlap significantly as they
localize to distinct parts of the Golgi/TGN (5D), therefore I have doubts over the robustness of this
readout. In Figure 5C colocalization of GPR161 and GolginA5 does not appear robust to me and is
not quantified. The images shown are low resolution and more detailed analysis is warranted.
Nocodazole treatment of cells to scatter the stacked Golgi would be useful here. 
 
The integrity of the microtubule network should be checked as disruption of this could result in
altered Golgi morphology (but not likely to secretion per se). The two phenotypes might be
unconnected. 
 
The conclusion that GPR161 might recruit GolginA5 is premature. The data do not provide
sufficient support for this. 
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The work by Popa and colleagues from the Moreau group reports on the identification of new regulators of
glycoprotein secretion using a CRISPR screen.
The manuscript is written well and is easy to follow. Most of the data are of strong quality and therefore, I
am supportive of the indexing of this work. I have a few concerns that could be easily addressed by a
revision.
The title implies that the paper identifies regulators of glycoprotein secretion. How sure are the
authors that these new proteins regulate glycoprotein trafficking, and not general trafficking? If they
want to maintain the prefix glyco-, then they should show that non-glycosylated proteins such as
albumin are not affected.
 
The authors use the term “Golgi fragmentation”, but this is not what I see. In many cases, the Golgi
is simply aberrant in shape (stretched, or extended). Is it possible to revisit the data to show
quantification of Golgi “fragments”? I think it is safer to use the term “aberrant Golgi structure”. The
authors could use the Golgi compactness index developed originally by Fred Bard (2003).
 
It is hard to appreciate the effects on ERES, with the magnification and image quality the authors
use. In my experience, a 20X magnification does not permit reliable judging of ERES. The authors
should do better ERES imaging and quantification for the 2-3 most important hits. Especially for
TMEM220, which they consider a regulator of ER-Golgi trafficking. This needs to be experimentally
supported.
 
The authors state/conclude that GRP161 serves to recruit GolginA5 to the Golgi. I don’t think that
the data support this claim. A similar perturbation of GolgiA5 staining is seen with TMEM220.
Could these not be simply a reflection of a distorted Golgi structure?
 
General comment: the work does not compare the results to previous screens by Rainer
Pepperkok , Hesso Farhan  and Fred Bard . I am not sure why the authors chose to ignore this
previous work, despite its obvious relevance to the current paper. Not only should these three
papers be cited, but a comparison of the hits should be made.
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